T1	Participants 220 277	patients with upper gastrointestinal adenocarcinoma (UGIA
T2	Participants 291 423	Seventy-three patients with advanced UGIA were randomised to receive 45 mg/m2 docetaxel or 180 mg/m2 irinotecan with 5-FU/leucovorin
T3	Participants 1349 1367	patients with UGIA
